Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.20
CRL's Cash to Debt is ranked lower than
87% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. CRL: 0.20 )
Ranked among companies with meaningful Cash to Debt only.
CRL' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.32 Max: N/A
Current: 0.2
Equity to Asset 0.37
CRL's Equity to Asset is ranked lower than
77% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. CRL: 0.37 )
Ranked among companies with meaningful Equity to Asset only.
CRL' s Equity to Asset Range Over the Past 10 Years
Min: -0.28  Med: 0.51 Max: 0.72
Current: 0.37
-0.28
0.72
Interest Coverage 13.22
CRL's Interest Coverage is ranked lower than
62% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 41.96 vs. CRL: 13.22 )
Ranked among companies with meaningful Interest Coverage only.
CRL' s Interest Coverage Range Over the Past 10 Years
Min: 4.09  Med: 8.70 Max: 14.87
Current: 13.22
4.09
14.87
F-Score: 6
Z-Score: 3.09
M-Score: -2.92
WACC vs ROIC
7.50%
11.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 15.38
CRL's Operating margin (%) is ranked higher than
84% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.55 vs. CRL: 15.38 )
Ranked among companies with meaningful Operating margin (%) only.
CRL' s Operating margin (%) Range Over the Past 10 Years
Min: -33.48  Med: 14.28 Max: 18.46
Current: 15.38
-33.48
18.46
Net-margin (%) 11.08
CRL's Net-margin (%) is ranked higher than
79% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.03 vs. CRL: 11.08 )
Ranked among companies with meaningful Net-margin (%) only.
CRL' s Net-margin (%) Range Over the Past 10 Years
Min: -38.84  Med: 9.17 Max: 12.55
Current: 11.08
-38.84
12.55
ROE (%) 21.62
CRL's ROE (%) is ranked higher than
92% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.34 vs. CRL: 21.62 )
Ranked among companies with meaningful ROE (%) only.
CRL' s ROE (%) Range Over the Past 10 Years
Min: -34.11  Med: 12.75 Max: 21.25
Current: 21.62
-34.11
21.25
ROA (%) 7.79
CRL's ROA (%) is ranked higher than
83% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.32 vs. CRL: 7.79 )
Ranked among companies with meaningful ROA (%) only.
CRL' s ROA (%) Range Over the Past 10 Years
Min: -21.02  Med: 5.98 Max: 7.58
Current: 7.79
-21.02
7.58
ROC (Joel Greenblatt) (%) 27.20
CRL's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -12.38 vs. CRL: 27.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CRL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -50.32  Med: 19.05 Max: 37.92
Current: 27.2
-50.32
37.92
Revenue Growth (3Y)(%) 7.00
CRL's Revenue Growth (3Y)(%) is ranked higher than
58% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. CRL: 7.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CRL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.1  Med: 7.00 Max: 10.9
Current: 7
-18.1
10.9
EBITDA Growth (3Y)(%) 8.30
CRL's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. CRL: 8.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CRL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.7  Med: 5.90 Max: 24.8
Current: 8.3
-18.7
24.8
EPS Growth (3Y)(%) 14.50
CRL's EPS Growth (3Y)(%) is ranked higher than
74% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.10 vs. CRL: 14.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CRL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -26  Med: 7.50 Max: 43.1
Current: 14.5
-26
43.1
» CRL's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

CRL Guru Trades in Q2 2015

Steven Cohen 185,000 sh (New)
Louis Moore Bacon 65,000 sh (New)
Jim Simons 1,082,609 sh (+30.54%)
Ken Fisher 508,316 sh (+26.30%)
Pioneer Investments 244,862 sh (+21.16%)
David Dreman 58,376 sh (+3.65%)
Westport Asset Management 155,000 sh (unchged)
PRIMECAP Management 1,622,300 sh (unchged)
Ray Dalio Sold Out
RS Investment Management Sold Out
John Rogers 1,679,650 sh (-4.48%)
Paul Tudor Jones 8,854 sh (-12.53%)
» More
Q3 2015

CRL Guru Trades in Q3 2015

Ray Dalio 19,687 sh (New)
Joel Greenblatt 29,055 sh (New)
Paul Tudor Jones 16,069 sh (+81.49%)
Pioneer Investments 292,807 sh (+19.58%)
David Dreman 61,274 sh (+4.96%)
Westport Asset Management 155,000 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
John Rogers 1,674,330 sh (-0.32%)
Ken Fisher 482,899 sh (-5.00%)
PRIMECAP Management 1,437,360 sh (-11.40%)
Jim Simons 816,209 sh (-24.61%)
» More
Q4 2015

CRL Guru Trades in Q4 2015

Steven Cohen 129,500 sh (New)
Paul Tudor Jones 20,336 sh (+26.55%)
Ken Fisher 516,495 sh (+6.96%)
Jim Simons 872,509 sh (+6.90%)
John Rogers 1,742,890 sh (+4.09%)
Westport Asset Management 155,000 sh (unchged)
David Dreman Sold Out
Joel Greenblatt Sold Out
Pioneer Investments 292,345 sh (-0.16%)
PRIMECAP Management 1,271,382 sh (-11.55%)
Ray Dalio 2,687 sh (-86.35%)
» More
Q1 2016

CRL Guru Trades in Q1 2016

Robert Olstein 24,286 sh (New)
Joel Greenblatt 70,227 sh (New)
David Dreman 57,090 sh (New)
Paul Tudor Jones 264,559 sh (+1200.94%)
Jim Simons 950,209 sh (+8.91%)
Ken Fisher 529,834 sh (+2.58%)
Pioneer Investments 293,498 sh (+0.39%)
Westport Asset Management 155,000 sh (unchged)
Ray Dalio Sold Out
John Rogers 1,666,955 sh (-4.36%)
PRIMECAP Management 1,213,160 sh (-4.58%)
Steven Cohen 104,600 sh (-19.23%)
» More
» Details

Insider Trades

Latest Guru Trades with CRL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LSE:0H1Z, NYSE:BIO, NAS:BRKR, NAS:ICLR, NAS:VWR » details
Traded in other countries:RV6.Germany,
Charles River Laboratories International Inc provides research models and services required to enable in vivo drug discovery and development.

Charles River Laboratories International Inc was incorporated in 1994 in Delaware and in 2000 it completed its initial public offering. Its portfolio includes research models and services required to enablein vivo drug discovery and development. Discovery represents the earliest stages of research in the life sciences, directed at the identification, screening and selection of a lead compound for future drug development. Discovery activities typically extend anywhere from 4-6 years in conventional pharmaceutical research and development timelines. Development activities, which follow, and which can take up to 7-10 years, are directed at demonstrating the safety, tolerability and clinical efficacy of the selected drug candidates. During the preclinical stage of the development process, a drug candidate is tested in vitro (typically on a cellular or sub-cellular level in a test tube or multi-well petri plate) and in vivo (in research models) to support planned or on-going human trials. The Company operates in two segments, namely Research Models and Services (RMS) and Preclinical Services (PCS). Through its RMS segment, the Company supplies research models to the drug development industry. It also provides a variety of related services that are designed to assist its clients in supporting the use of research models in drug discovery and development. With multiple facilities located on three continents (North America, Europe and Asia), it maintains production centers, including barrier rooms and/or isolator facilities. Its PCS business segment provides services that enable its clients to outsource their critical, regulatory-required safety assessment and related drug development activities to the Company. Its RMS segment is comprised of Research Models, Research Model Services and Endotoxin and Microbial Detection. Its Research Models business is comprised of the production and sale of research models and avian vaccine services. Research Model Services also offers a variety of services designed to support its clients' use of research models in screening drug candidates. Its Endotoxin and Microbial Detection business provides non-animal, or in vitro, methods for lot release testing of medical devices and injectable drugs for endotoxin contamination. The Company currently offers preclinical services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Company's customers include global biopharmaceutical companies, small and mid-sized pharmaceutical companies and biotechnology companies, and academic and government institutions. The Company competes in the marketplace on the basis of therapeutic and scientific expertise in in vivo biology, quality, reputation, flexibility, responsiveness, pricing, innovation and global capabilities. The Company's business operates in a num

Guru Investment Theses on Charles River Laboratories International Inc

John Rogers Comments on Charles River Laboratories Intl Inc - Jul 22, 2014

Preclinical testing firm Charles River Laboratories Intl, Inc. (CRL) dropped –11.30% as mergers and acquisitions ramped up in the health-care sector. Health-care consolidations have been rising, the most prominent being a proposed $100 billion acquisition of Astra-Zeneca by Pfizer Inc. (PFE), and with mergers come the rationalization of research capabilities. The market tends to react swiftly and sharply to such events. We think such reactions are generally overblown, as the effects tend to be more short-term than long-term; as such we think Charles River has become a better bargain lately.

From John Rogers (Trades, Portfolio)' Ariel Fund Second Quarter 2014 Commentary.

Check out John Rogers latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 26.39
CRL's P/E(ttm) is ranked higher than
56% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.11 vs. CRL: 26.39 )
Ranked among companies with meaningful P/E(ttm) only.
CRL' s P/E(ttm) Range Over the Past 10 Years
Min: 8.59  Med: 24.47 Max: 95.93
Current: 26.39
8.59
95.93
Forward P/E 17.04
CRL's Forward P/E is ranked higher than
71% of the 41 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. CRL: 17.04 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 26.23
CRL's PE(NRI) is ranked higher than
54% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.11 vs. CRL: 26.23 )
Ranked among companies with meaningful PE(NRI) only.
CRL' s PE(NRI) Range Over the Past 10 Years
Min: 8.48  Med: 24.08 Max: 77.86
Current: 26.23
8.48
77.86
Price/Owner Earnings (ttm) 17.18
CRL's Price/Owner Earnings (ttm) is ranked higher than
78% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.91 vs. CRL: 17.18 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CRL' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.36  Med: 20.49 Max: 93.06
Current: 17.18
9.36
93.06
P/B 5.20
CRL's P/B is ranked lower than
70% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.20 vs. CRL: 5.20 )
Ranked among companies with meaningful P/B only.
CRL' s P/B Range Over the Past 10 Years
Min: 0.75  Med: 2.48 Max: 6
Current: 5.2
0.75
6
P/S 2.92
CRL's P/S is ranked higher than
52% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. CRL: 2.92 )
Ranked among companies with meaningful P/S only.
CRL' s P/S Range Over the Past 10 Years
Min: 1.11  Med: 2.29 Max: 3.88
Current: 2.92
1.11
3.88
PFCF 16.04
CRL's PFCF is ranked higher than
74% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.82 vs. CRL: 16.04 )
Ranked among companies with meaningful PFCF only.
CRL' s PFCF Range Over the Past 10 Years
Min: 8.62  Med: 17.14 Max: 765.42
Current: 16.04
8.62
765.42
POCF 12.95
CRL's POCF is ranked higher than
66% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.23 vs. CRL: 12.95 )
Ranked among companies with meaningful POCF only.
CRL' s POCF Range Over the Past 10 Years
Min: 4.79  Med: 12.48 Max: 20.15
Current: 12.95
4.79
20.15
EV-to-EBIT 20.44
CRL's EV-to-EBIT is ranked lower than
51% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.25 vs. CRL: 20.44 )
Ranked among companies with meaningful EV-to-EBIT only.
CRL' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.7  Med: 17.60 Max: 27.6
Current: 20.44
-10.7
27.6
EV-to-EBITDA 14.40
CRL's EV-to-EBITDA is ranked higher than
51% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.54 vs. CRL: 14.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.5  Med: 11.90 Max: 16.6
Current: 14.4
-16.5
16.6
Shiller P/E 251.51
CRL's Shiller P/E is ranked lower than
100% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.66 vs. CRL: 251.51 )
Ranked among companies with meaningful Shiller P/E only.
CRL' s Shiller P/E Range Over the Past 10 Years
Min: 97.7  Med: 147.40 Max: 1940.5
Current: 251.51
97.7
1940.5
Current Ratio 2.06
CRL's Current Ratio is ranked lower than
61% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.54 vs. CRL: 2.06 )
Ranked among companies with meaningful Current Ratio only.
CRL' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 2.05 Max: 3.49
Current: 2.06
1.21
3.49
Quick Ratio 1.74
CRL's Quick Ratio is ranked lower than
62% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.28 vs. CRL: 1.74 )
Ranked among companies with meaningful Quick Ratio only.
CRL' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 1.73 Max: 3.02
Current: 1.74
0.95
3.02
Days Inventory 40.15
CRL's Days Inventory is ranked higher than
71% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.76 vs. CRL: 40.15 )
Ranked among companies with meaningful Days Inventory only.
CRL' s Days Inventory Range Over the Past 10 Years
Min: 38.5  Med: 41.44 Max: 49.49
Current: 40.15
38.5
49.49
Days Sales Outstanding 61.38
CRL's Days Sales Outstanding is ranked higher than
52% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.64 vs. CRL: 61.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.42  Med: 59.51 Max: 69.89
Current: 61.38
53.42
69.89
Days Payable 18.95
CRL's Days Payable is ranked lower than
88% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 56.70 vs. CRL: 18.95 )
Ranked among companies with meaningful Days Payable only.
CRL' s Days Payable Range Over the Past 10 Years
Min: 14.74  Med: 15.67 Max: 17.81
Current: 18.95
14.74
17.81

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 50.43
CRL's Price/Tangible Book is ranked lower than
98% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.81 vs. CRL: 50.43 )
Ranked among companies with meaningful Price/Tangible Book only.
CRL' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.86  Med: 7.10 Max: 350.94
Current: 50.43
2.86
350.94
Price/Projected FCF 1.62
CRL's Price/Projected FCF is ranked higher than
64% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.23 vs. CRL: 1.62 )
Ranked among companies with meaningful Price/Projected FCF only.
CRL' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.95  Med: 1.33 Max: 1.75
Current: 1.62
0.95
1.75
Price/Median PS Value 1.28
CRL's Price/Median PS Value is ranked lower than
71% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. CRL: 1.28 )
Ranked among companies with meaningful Price/Median PS Value only.
CRL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.54  Med: 1.15 Max: 1.8
Current: 1.28
0.54
1.8
Price/Graham Number 7.67
CRL's Price/Graham Number is ranked lower than
92% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.07 vs. CRL: 7.67 )
Ranked among companies with meaningful Price/Graham Number only.
CRL' s Price/Graham Number Range Over the Past 10 Years
Min: 1.65  Med: 2.95 Max: 17.99
Current: 7.67
1.65
17.99
Earnings Yield (Greenblatt) (%) 4.90
CRL's Earnings Yield (Greenblatt) (%) is ranked higher than
76% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.50 vs. CRL: 4.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CRL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.6  Med: 5.50 Max: 14.1
Current: 4.9
3.6
14.1
Forward Rate of Return (Yacktman) (%) 9.33
CRL's Forward Rate of Return (Yacktman) (%) is ranked higher than
50% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.33 vs. CRL: 9.33 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CRL' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 2.8  Med: 5.60 Max: 23
Current: 9.33
2.8
23

More Statistics

Revenue (TTM) (Mil) $1,398
EPS (TTM) $ 3.26
Beta0.92
Short Percentage of Float3.89%
52-Week Range $59.99 - 86.45
Shares Outstanding (Mil)47.18

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1,647 1,816 1,941
EPS ($) 4.36 5.05 5.49
EPS without NRI ($) 4.36 5.05 5.49
EPS Growth Rate
(3Y to 5Y Estimate)
12.68%
» More Articles for CRL

Headlines

Articles On GuruFocus.com
Weekly Highlight of CEO Sells Oct 13 2014 
John Rogers Comments on Charles River Laboratories Intl Inc Jul 22 2014 
John Rogers' Ariel Fund Second Quarter 2014 Commentary Jul 22 2014 
Robert Olstein’s Largest New Stock Picks Feb 12 2013 
Weekly CFO Sells HIGHLIGHT: TMO, BLOX, VRSK, CRL, INGR, GWRE Jan 13 2013 
Ariel Funds Top Buys: "We think like Halvorsen: CRL is a buy" Jan 11 2012 
Stocks I Can Buy Much Cheaper Than Halvorsen Did Jan 11 2012 
Ken Heebner Top Holdings: AAPL Is a Buy at $380 Jan 11 2012 
Charles River Laboratories International Reports Operating Results (10-Q) Nov 04 2010 
Charles River Laboratories International Reports Operating Results (10-Q) Aug 03 2010 

More From Other Websites
CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K/A, Change in Directors or Principal... May 16 2016
CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Amendments to Articles of Inc. or... May 16 2016
ETF’s with exposure to Charles River Laboratories International, Inc. : May 12, 2016 May 12 2016
CHARLES RIVER LABORATORIES INTERNATIONAL INC Financials May 10 2016
Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: Q1, 2016 By the Numbers May 10 2016
Edited Transcript of CRL earnings conference call or presentation 4-May-16 12:30pm GMT May 04 2016
Charles River Laboratories International Inc Earnings Call scheduled for 8:30 am ET today May 04 2016
Charles River beats Street 1Q forecasts May 04 2016
Charles River beats Street 1Q forecasts May 04 2016
CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial... May 04 2016
Q1 2016 Charles River Laboratories International Inc Earnings Release - Before Market Open May 04 2016
Charles River Laboratories Announces First-Quarter 2016 Results from Continuing Operations May 04 2016
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Molina Healthcare, PAREXEL International,... Apr 27 2016
Street Talk: CAT, TCS, NEM & more Apr 26 2016
5 Stocks to Invest on Healthcare Rebound Apr 26 2016
Coverage initiated on Charles River by Gabelli & Co Apr 26 2016
Charles River Laboratories and BioMotiv Enter into Strategic Partnership Apr 13 2016
Charles River Laboratories and BioMotiv Enter into Strategic Partnership Apr 13 2016
Charles River Laboratories Schedules First-Quarter 2016 Earnings Release and Conference Call Apr 07 2016
Charles River Laboratories Schedules First-Quarter 2016 Earnings Release and Conference Call Apr 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)